LifeCodexx | GenomeWeb


Last week, the G-BA, a committee that decides about reimbursable medical services in Germany, said it will start a methods evaluation of noninvasive prenatal testing.

The tech transfers are aided by LifeCodexx's PrenaBoxx NIPT data analysis solution, which runs locally and can analyze both NGS and qPCR data.

Several new laboratories started to offer NIPT locally in 2015, and some providers have been shifting to less-expensive non-NGS platforms. 

Prices in Germany for noninvasive prenatal testing have plummeted over the last year, driven by competition and process improvements.

OKP will pay for testing if standard first trimester screening indicates a risk higher than 1:1000 for trisomies 21, 18, or 13.

The new test promises lower cost, faster turnaround time, and easier implementation than current NIPT, which rely on next-generation sequencing or microarray analysis.

NEW YORK (GenomeWeb) − Competition for non-invasive prenatal testing in Germany is heating up, with Illumina announcing this week that it has teamed up with a German diagnostic laboratory and other European labs to transfer Verinata's test technology to those countries, and LifeCodexx saying last

LifeCodexx's PrenaTest for noninvasive detection of fetal anueploidies is now available for use in multiple pregnancies. It can also be used following fertility treatment, such as in vitro fertilization or egg donation after the 9th week of gestation.

GATC Biotech subsidiary LifeCodexx has launched a new version of its noninvasive fetal aneuploidy test, PraenaTest Express, that has a turnaround time of one week.

GATC Biotech subsidiary LifeCodexx has updated its noninvasive sequencing-based PrenaTest for fetal trisomies so that it can be performed in high-risk pregnancies as early as nine weeks.


In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.